Neurogene Inc (NAS:NGNE)
$ 25.43 -0.37 (-1.43%) Market Cap: 377.76 Mil Enterprise Value: 253.30 Mil PE Ratio: 0 PB Ratio: 2.41 GF Score: 20/100

Q4 2021 Neoleukin Therapeutics Inc Earnings Call Transcript

Mar 01, 2022 / 09:30PM GMT
Operator

Good afternoon, and thank you for joining us today for Neoleukin Therapeutics conference call. (Operator Instructions) As a reminder, today's conference call is being recorded. I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin Therapeutics. Julie, Please go ahead.

Julie Rathbun;Rathbun Communications;President

Thank you. Good afternoon, and welcome to Neoleukin Therapeutics Year-End 2021 Conference Call. Joining me on the call today from Neoleukin are Jonathan Drachman, CEO; Priti Patel, CMO; and Sean Smith, Vice President, Finance. Today's call is being recorded. It will be available for replay on the Investor Relations section of the Neoleukin website approximately 2 hours after the call for at least 30 days.

Before we start, I'd like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgments, intentions, beliefs and expectations about future events, strategies, product candidates and operating

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot